Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation
Authors:
- Wolfgang HerrWHWolfgang Herr
- Bodo PlachterBPBodo Plachter
- 1 August 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 8 (8) , 999-1021
Abstract
Impairment of cellular immunity upon hematopoietic stem cell transplantation (HSCT) may lead to serious clinical manifestations induced by human cytomegalovirus (HCMV) and varicella-zoster virus (VZV) infections. Although the clinical presentations, preferential organ involvement and clinical courses are different, infections with both herpesviruses are similar with respect to many pathophysiological aspects and the therapeutic strategies that are employed to combat them. Antiviral drug prophylaxis and therapy are successfully used to limit the risk of reactivated HCMV and VZV infections, but are unable to absolutely prevent episodes of virus disease in long-term follow-up after HSCT. Control of infection requires the re-establishment of protective antiviral cellular immunity in the host. Here we review the most recent developments in the field of HCMV and VZV immunotherapy with specific emphasis on the question of how vaccines against HCMV and VZV may aid in enhancing the reconstitution of antiviral immunity after HSCT, and thereby support the control of these two agents by transplant recipients.Keywords
This publication has 214 references indexed in Scilit:
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infectionVaccine, 2008
- HCMV gH/gL/UL128–131 interferes with virus entry into epithelial cells: Evidence for cell type-specific receptorsProceedings of the National Academy of Sciences, 2008
- A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirusVaccine, 2008
- A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vectorVirology, 2008
- Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirusVaccine, 2007
- Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1Vaccine, 2006
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsJournal of Experimental Medicine, 2005
- Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirusNature Immunology, 2005
- Prevention of transfusion-acquired cytomegalovirus infections in newborn infantsThe Journal of Pediatrics, 1981